A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf
.
Pharmacogenetics in Europe: Barriers and Opportunities
2009
Public Health Genomics
sector to invest in the development and licensing of PGx diagnostic tests for improving the safety and efficacy of outof-patent drugs. It therefore seems that one key aspect where policy can affect the clinical uptake of PGx is via sustaining large-scale industry-academia collaborations for developing and proving the utility of PGx diagnostics.
doi:10.1159/000189625
pmid:19204415
fatcat:s2v36h2sqzgg5jz47txsowtzae